Loading
Fortress Biotech, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by ROSENWALD LINDSAY A MD, was filed 25 Sept 2024.
Fortress Biotech, Inc.: what insiders have been doing
Fortress Biotech, Inc., classified in the Health Care sector, is a listed company. Its insiders report their share dealings to SEC (Form 4). 8 insiders have disclosed 10 filings since 22 October 2025.
The filings describe grants, exercises and other transfers rather than trades on the open market. Because grants and exercises are largely decided by remuneration plans, they are not counted as purchases here.
For context, the typical company on the same exchange (median of 3,171 companies) published 24 filings over the same period, against 10 filings here. Looking back to 2016, when coverage begins, insiders filed 33 purchases and 16 sales. The 10-K for the year ended 31 December 2025 shows 63.3 m USD of revenue and 6.8 m USD of net income.
There has been no open-market purchase by an insider of Fortress Biotech, Inc. for at least a year. The median gap between a trade and its publication by SEC (Form 4) is 4 days. Section 16 rules allow two business days to file each Form 4.
This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Insider Decl.
161
Thresholds
n/a
Buy Volume
€10M
33 ops. · all time
Sell Volume
€711,175
16 ops. · all time
Since the insiders bought
- +169.7%Entry US$1.45 · Close at T+365 US$3.91
- -2.0%Entry US$2.00 · Close at T+365 US$1.96
- -29.2%Entry US$2.09 · Close at T+365 US$1.48
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 17,620 of 26,250 companies
40.3
score / 100
Value12
Quality69
FCF yld-102%
Earn yld-2.9%
EV/EBITDA·
ROE116%
Gross mgn67%
Net mgn-3.0%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$1.94
Analyst consensus
1 analysts1.00/5
US$5.00Target US$5.00(+158%)US$5.00
Income statement
RevenueUS$63.3M
Gross profitUS$42.3M67% margin
EBITDA-US$20.2M-32% margin
Net income-US$1.9M163.3% margin
Valuation
PER (trailing)0.7x
P/Book0.4x
Beta1.25
Balance sheet & cash
Market capUS$64.7M
Total debtUS$74.3M
Free Cash Flow-US$65.8M
Debt / Equity26%
Profitability & ownership
ROE116.0%
ROA-7.8%
% insiders23.9%
% institutions31.2%
Last declaration on 1 October 2026
Declarations161 total
1,190 shares@ US$1.8190.0030% mcap3.4% of flowCommon Stock, par value $0.001SEC:0001930732-26-000006:0
400,000 sharesCommon Stock, par value $0.001SEC:0001930732-26-000003:0
2,967 shares@ US$2.17610.1% of flowCommon Stock, par value $0.001SEC:0001930732-26-000002:0
475,424 shares0Common stock, par value $0.001SEC:0000941841-26-000002:0
475,424 shares0common stock, par value $0.001SEC:0001038977-26-000002:0
27,322 shares0common stock, par value $0.001SEC:0001772558-26-000002:0
27,322 shares0common stock, par value $0.001SEC:0001647971-26-000002:0
27,322 shares0common stock, par value $0.001SEC:0001529687-26-000002:0
27,322 shares0Common Stock, par value $0.001SEC:0001294517-26-000002:0
27,322 shares0common stock, par value $0.001SEC:0001172659-26-000002:0
2,711 shares@ US$1.3095.5% of flowCommon Stock, par value $0.001SEC:0001930732-25-000004:0
5,000 shares@ US$1.215510.2% of flowCommon Stock, par value $0.001SEC:0001415889-25-009369:0
49,383 shares0common stock, par value $0.001SEC:0001415889-25-000428:0
49,383 shares0Common Stock, par value $0.001SEC:0001415889-25-000425:0
49,383 shares0common stock, par value $0.001SEC:0001415889-25-000444:0
49,383 shares0common stock, par value $0.001SEC:0001415889-25-000427:0
454,153 shares0Common stock, par value $0.001SEC:0001415889-25-000400:0
49,383 shares0common stock, par value $0.001SEC:0001415889-25-000429:0
454,153 shares0common stock, par value $0.001SEC:0001415889-25-000402:0
49,383 shares0common stock, par value $0.001SEC:0001415889-25-000426:0
1,000,000 shares0Common Stock, par value $0.001SEC:0001415889-24-030071:0
2,625 shares@ US$1.22835.3% of flowCommon Stock, par value $0.001SEC:0001415889-24-024183:0
763,359 shares@ US$1.8420.5% of flowCommon stock, par value $0.001SEC:0001415889-24-023957:0
Canonical exit: 22 Dec 2024 (T+90)
5,000 shares@ US$7.48350.6% of flowSERIES A CUMULATIVE PERPETUAL PREFERRED STOCKSEC:0001104659-24-079855:0
Canonical exit: 9 Oct 2024 (T+90)
500 shares@ US$7.506.3% of flowSERIES A CUMULATIVE PERPETUAL PREFERRED STOCKSEC:0001104659-24-079409:0
Canonical exit: 8 Oct 2024 (T+90)
25 of 161 declarations
About Fortress Biotech, Inc.
Fortress Biotech, Inc. is a company focused on developing innovative therapies for the treatment of diseases. It primarily operates in the healthcare and pharmaceutical sector, listed on NASDAQ.
